1
|
Owaidah T, Almomen A, Tarawah A, Warsi A, Alkasim F, Alzahrani H, Saleh M, Kashari O, Jastaniah W. Consensus recommendations on appropriate coagulation tests during emicizumab administration in Saudi Arabia. Am J Blood Res 2022; 12:82-87. [PMID: 35873100 PMCID: PMC9301022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Accepted: 05/05/2022] [Indexed: 06/15/2023]
Abstract
INTRODUCTION Emicizumab is a bispecific monoclonal antibody with the ability to bridge FIXa and FX, mimic FVIII, and restore normal hemostasis in patients with hemophilia A. Moreover, substantial evidence has shown that emicizumab-treated patients do not require monitoring, except before surgery or invasive procedures. However, introducing this novel drug to the market poses some challenges to physicians and clinical laboratories due to its interaction with conventional coagulation tests. METHODS Given the challenges and laboratory interactions posed by this novel drug, there is an unmet clinical need to develop clear recommendations for emicizumab laboratory monitoring to highlight which laboratory tests should be used, which tests should be avoided, and when these tests should be performed. These expert recommendations are essential to prevent inappropriate testing or misleading interpretations and reduce the extra costs of unnecessary monitoring. RESULTS A consensus meeting was conducted in December 2019, including top experts on hemophilia from Saudi Arabia, to discuss this issue. CONCLUSION The experts agreed that, aPTT (activated Partial Thromboplastin Time)-based tests are not suitable for laboratory monitoring patients treated with emicizumab. Only FVIII chromogenic assays based on bovine FIX and FX proteins can be used to measure FVIII levels. They reviewed and recommended the type and time of testing for anti-factor VIII antibodies. Drug levels should be measured using the recommended test only when the anti-drug antibody (ADA) is clinically suspected and after excluding other causes (such as patient non-compliance).
Collapse
Affiliation(s)
- Tarek Owaidah
- Hematology and Transfusion Medicine, Department of Pathology and Laboratory Medicine (MBC 10), King Faisal Specialist Hospital and Research Center Alfaisal UniversityRiyadh, Saudi Arabia
| | - Abdulakareem Almomen
- Medicine-Hematology, King Saud University Medical City and Blood and Cancer CenterRiyadh, Saudi Arabia
| | - Ahmed Tarawah
- Paediatric Haematology, Madina Maternity and Children HospitalMedina, Saudi Arabia
| | - Ashraf Warsi
- Adult Haematology, College of Medicine, Umm Al-Qura University, Mecca, Saudi Arabia; Princess Norah Oncology Centre, King Abdelaziz Medical City, Ministry of National Guard Health Affairs-WRJeddah, Saudi Arabia
| | - Fawaz Alkasim
- Paediatric Haematology, Maternity and Children HospitalRiyadh, Saudi Arabia
| | - Hazzaa Alzahrani
- Adult Haematology, King Faisal Specialist Hospital and Research CentreRiyadh, Saudi Arabia
| | - Mahassen Saleh
- Paediatric Haematology, King Faisal Specialist Hospital and Research CentreRiyadh, Saudi Arabia
| | - Ohoud Kashari
- Paediatric Haematology, East Jeddah General HospitalJeddah, Saudi Arabia
| | - Wasil Jastaniah
- Pediatrics and Pediatric Hematology/Oncology/BMT, College of Medicine, Umm Al-Qura UniversityMecca, Saudi Arabia
- Princess Norah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs WRJeddah, Saudi Arabia
| |
Collapse
|
2
|
Alsultan A, Aljefri A, Ayas M, Alharbi M, Alkhayat N, Al-Anzi F, Yassin F, Alkasim F, Alharbi Q, Abdullah S, Abrar M, Jastaniah W. Travel burden and geographic access to health care among children with cancer in Saudi Arabia. East Mediterr Health J 2020; 26:1355-1362. [PMID: 33226103 DOI: 10.26719/emhj.20.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/10/2019] [Accepted: 11/13/2019] [Indexed: 11/09/2022]
Abstract
Background Travel burden has a substantial psychosocial impact and financial strain on childhood cancer patients and their families. Aims To study the geographic distribution of childhood cancer and assess the travel burden for care in Saudi Arabia. Methods This was a cross-sectional multi-institutional study that enrolled 1657 children with cancer who were diagnosed between 2011 and 2014. Cancer type/stage, city/region of residence, and city/region of treating centre were recorded. Travel burden was measured based on a 1-way distance in kilometres from the city centre to the treatment institution. This study was supported by Sanad Children's Cancer Support Association. Results Diagnosis was leukaemia (45.2%), non-CNS solid tumours (30.2%), lymphoma (12.3%), CNS tumours (11.8%) and histiocytosis (0.5%). Childhood cancer centres were in the same city as where the patients lived in 652 (39.3%) cases, same region but different city in 308 (18.6%), different regions in 613 (37%), and not known in 84 (5.1%). The mean 1-way travel distance for patients who lived in different regions was 790 (range, 116-1542) km. A total of 536 (32%) patients lived ≥ 400 km and 216 (13%) > 1000 km from the treatment centre. Among 642 patients with acute lymphoblastic leukaemia who required 2-3 years of therapy, 197 (31%) lived ≥ 400 km and 94 (15%) >1000 km from the treatment centre. Conclusions Nearly two thirds of patients with childhood cancer lived in different cities than the treatment centres, including one third of patients who lived ≥ 400 km away. There is a need to develop strategies to improve access to childhood cancer care.
Collapse
Affiliation(s)
- Abdulrahman Alsultan
- Department of Pediatrics, College of Medicine, King Saud University, Riyadh, Saudi Arabia.,Department of Pediatric Hematology/Oncology, King Abdullah Specialist Children's Hospital, Riyadh, Saudi Arabia
| | - Abdullah Aljefri
- Department of Pediatric Hematology/Oncology, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
| | - Mouhab Ayas
- Department of Pediatric Hematology/Oncology, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
| | - Musa Alharbi
- Department of Pediatric Hematology/Oncology, Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia
| | - Nawaf Alkhayat
- Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
| | - Faisal Al-Anzi
- Prince Faisal Bin Bandar Cancer Center, Qassim, Saudi Arabia
| | - Fawwaz Yassin
- Department of Pediatric Hematology/Oncology, King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia
| | - Fawaz Alkasim
- Department of Pediatric Hematology and Oncology, King Saud Medical City, Riyadh, Saudi Arabia
| | - Qasim Alharbi
- Department of Pediatric Hematology/Oncology, King Fahad Specialist Hospital, Dammam, Saudi Arabia
| | - Shaker Abdullah
- Department of Oncology, Princess Noorah Oncology Center, King Saud Bin Abdulaziz University and King Abdulaziz Medical City, Jeddah, Saudi Arabia
| | - Mohammed Abrar
- Department of Oncology, Princess Noorah Oncology Center, King Saud Bin Abdulaziz University and King Abdulaziz Medical City, Jeddah, Saudi Arabia
| | - Wasil Jastaniah
- Department of Oncology, Princess Noorah Oncology Center, King Saud Bin Abdulaziz University and King Abdulaziz Medical City, Jeddah, Saudi Arabia.,Department of Pediatrics, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
| |
Collapse
|
3
|
Alsultan A, Essa M, Aljefri A, Ayas M, Alharbi M, Alkhayat N, Al-Anzi F, Yassin F, Alkasim F, Alharbi Q, Abdullah S, Jastaniah W. Frequency of pathogenic/likely pathogenic germline variants in cancer-related genes among children with acute leukemia in Saudi Arabia. Pediatr Blood Cancer 2020; 67:e28340. [PMID: 32359129 DOI: 10.1002/pbc.28340] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/21/2020] [Revised: 03/09/2020] [Accepted: 03/30/2020] [Indexed: 12/13/2022]
Abstract
BACKGROUND The frequency of pathogenic/likely pathogenic (P/LP) germline mutations in cancer-related genes among children with cancer in highly consanguineous populations is not well studied. METHODS Whole-exome sequencing of germline DNA was performed in 60 children with acute leukemia. We used the St. Jude Pediatric Cancer Variant Pathogenicity Information Exchange (PeCanPIE) data portal for the classification of germline variants by the St. Jude Medal Ceremony pipeline. RESULTS Fifty-seven patients had acute lymphoblastic leukemia (ALL) and three patients had acute myeloid leukemia. Parental consanguinity was present in 27 (45%) patients. All patients were of Arab ancestry. Three patients (5%) had a history of cancer in their siblings. Five patients (8.3%) had P/LP germline mutations in cancer-related genes. Three patients with B-ALL had heterozygous pathogenic mutations in TP53, BRCA1, and BRCA2; one patient with B-ALL had homozygous pathogenic mutation in PMS2; and one patient with T-ALL had LP homozygous mutation in AK2 that was associated with reticular dysgenesis. Among patients who had history of parental consanguinity, three (11%) had P/LP germline mutations compared with two (8%) in the absence of parental consanguinity. Fourteen (23%) patients had gold medal variants in cancer-related genes, 13 were heterozygous, and one was homozygous. Silver medal variants were present in 35 (58%) patients; all were heterozygous except one homozygous. CONCLUSIONS Children with acute leukemia in Saudi Arabia had low frequency of P/LP mutations in cancer-related genes despite the high rate of consanguinity. Larger studies using whole-genome sequencing are needed to further explore the heritability of childhood leukemia.
Collapse
Affiliation(s)
- Abdulrahman Alsultan
- Department of Pediatrics, College of Medicine, King Saud University, Riyadh, Saudi Arabia
| | - Mohammed Essa
- Department of Pediatric Hematology/Oncology, King Abdullah Specialist Children's Hospital, Riyadh, Saudi Arabia.,College of Medicine, Ministry of National Guard Health Affairs, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
| | - Abdullah Aljefri
- Department of Pediatric Hematology/Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Mouhab Ayas
- Department of Pediatric Hematology/Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Musa Alharbi
- Department of Pediatric Hematology/Oncology, Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia
| | - Nawaf Alkhayat
- Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
| | - Faisal Al-Anzi
- Prince Faisal Bin Bandar Cancer Center, Qassim, Saudi Arabia
| | - Fawwaz Yassin
- Department of Pediatric Hematology/Oncology, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia
| | | | - Qasim Alharbi
- Department of Pediatric Hematology/Oncology, King Fahad Specialist Hospital, Dammam, Saudi Arabia
| | - Shaker Abdullah
- Department of Oncology, Princess Noorah Oncology Center, King Saud Bin Abdulaziz University and King Abdulaziz Medical City, Jeddah, Saudi Arabia
| | - Wasil Jastaniah
- Department of Oncology, Princess Noorah Oncology Center, King Saud Bin Abdulaziz University and King Abdulaziz Medical City, Jeddah, Saudi Arabia.,Department of Pediatrics, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
| |
Collapse
|
4
|
Goga Y, Boukari R, Bensadok M, El Khorassani M, Khelif A, Al Rawas A, Alkasim F, Shaheen NM, Negrier C. REACH: A programme for improving care in haemophilia. Haemophilia 2019; 25:e211-e215. [PMID: 30888109 DOI: 10.1111/hae.13726] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/12/2019] [Indexed: 12/01/2022]
Affiliation(s)
- Yasmin Goga
- Department of Paediatrics & Child Health, Inkosi Albert Luthuli Central Hospital, Durban, South Africa
| | - Rachida Boukari
- Paediatric Department, University Hospital Mustapha Pacha, Algiers, Algeria
| | - Meriem Bensadok
- Haematology and Blood Bank, Haemophilia Treatment Centre, Beni-Messous University Hospital, Algiers, Algeria
| | - Mohamed El Khorassani
- Haemophilia Treatment Centre, Haematology and Oncology Unit, Mohammed V University Hospital, Rabat, Morocco
| | | | | | | | | | - Claude Negrier
- Louis Pradel Hospital, University Claude Bernard, Lyon, France
| |
Collapse
|
5
|
Jastaniah W, Aljefri A, Ayas M, Alharbi M, Alkhayat N, Al-Anzi F, Yassin F, Alkasim F, Alharbi Q, Abdullah S, Abrar MB, Alsultan A. Prevalence of hereditary cancer susceptibility syndromes in children with cancer in a highly consanguineous population. Cancer Epidemiol 2018; 55:88-95. [PMID: 29859499 DOI: 10.1016/j.canep.2018.05.006] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2018] [Revised: 05/08/2018] [Accepted: 05/15/2018] [Indexed: 11/19/2022]
Abstract
BACKGROUND & AIM Hereditary cancer susceptibility syndromes (HCSS) are reported in up to one-third of children with cancer. Diagnosis of HCSS is crucial for implementation of surveillance protocols. We identified children who fulfilled criteria for HCSS in Saudi Arabia using the American College of Medical Genetics and Genomics (ACMG) guidelines, addressing the utility of these guidelines in a highly consanguineous population. METHODS This multi-center cross-sectional study recruited 1858 children with cancer between January 2011 and December 2014. HCSS criteria were based on the ACMG guidelines. RESULTS Seven hundred and four (40.4%) out of 1742 eligible patients fulfilled criteria for HCSS. Consanguinity was reported in 629 (38%) patients, with 50 (2.9%) first-degree, 535 (30.7%) second-degree, and 272 (15.6%) third-degree relatives affected with cancer. Two hundred and eighty eight (17.4%) leukemia and 87 (5.3%) brain tumour patients fulfilled HCSS criteria, with parental consanguinity being the most frequent criterion in both (leukemia 85.4%, brain tumors 83.9%). However, leukemia was less frequent in patients of consanguineous parents (p = 0.023). CONCLUSION Four out of 10 children with cancer fulfilled criteria for HCSS, most often due to consanguinity. This higher than expected prevalence suggests the need to validate consanguinity as a criterion for HCSS in highly consanguineous populations.
Collapse
Affiliation(s)
- Wasil Jastaniah
- Department of Pediatrics, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia; Chairman Princess Noorah Oncology Center, King Saud Bin Abdulaziz University and King Abdulaziz Medical City, Jeddah, Saudi Arabia.
| | - Abdullah Aljefri
- Consultant Pediatric Hematology/Oncology/BMT, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
| | - Mouhab Ayas
- Consultant Pediatric Hematology/Oncology/BMT, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
| | - Musa Alharbi
- Consultant Pediatric Hematology/Oncology/BMT and Chairman of the Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia
| | - Nawaf Alkhayat
- Consultant Pediatric Hematology/Oncology/BMT, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
| | - Faisal Al-Anzi
- Chief Executive Officer and Consultant Pediatric Hematology/Oncology/BMT, Prince Faisal Bin Bandar Cancer Center, Qaseem, Saudi Arabia
| | - Fawwaz Yassin
- Consultant Pediatric Hematology/Oncology/BMT, King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia
| | - Fawaz Alkasim
- Consultant Pediatric Hematology/Oncology/BMT, King Saud Medical City, Riyadh, Saudi Arabia
| | - Qasim Alharbi
- Consultant Pediatric Hematology/Oncology/BMT, King Fahad Specialist Hospital, Dammam, Saudi Arabia
| | - Shaker Abdullah
- Consultant Pediatric Hematology/Oncology/BMT and Head Section of Pediatric Hematology/Oncology/BMT, Princess Noorah Oncology Center, King Saud Bin Abdulaziz University and King Abdulaziz Medical City, Jeddah, Saudi Arabia
| | - Mohammed Burhan Abrar
- Princess Noorah Oncology Center, King Saud Bin Abdulaziz University and King Abdulaziz Medical City, Jeddah, Saudi Arabia
| | - Abdulrahman Alsultan
- Department of Pediatrics, College of Medicine, King Saud University, Riyadh, Saudi Arabia; Consultant Pediatric Hematology/Oncology/BMT, Department of Pediatric Hematology/Oncology, King Abdullah Specialist Children's Hospital, Riyadh, Saudi Arabia
| |
Collapse
|
6
|
Owaidah T, Momen AA, Alzahrani H, Almusa A, Alkasim F, Tarawah A, Nouno RA, Batniji FA, Alothman F, Alomari A, Abu-Herbish S, Abu-Riash M, Siddiqui K, Ahmed M, Mohamed SY, Saleh M. The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program. Medicine (Baltimore) 2017; 96:e5456. [PMID: 28079788 PMCID: PMC5266150 DOI: 10.1097/md.0000000000005456] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Hemophilia A and B are X-linked diseases that predominantly affect male patients. Patients can develop coagulation factor inhibitors, which exponentially increases the treatment cost. However, the prevalence of factor VIII and IX inhibitors in Saudi Arabia is unclear.This study aimed to determine the Saudi prevalence of factor VIII and IX inhibitors.This 4-year, 7-center, cross-sectional study evaluated the Saudi prevalences of hemophilia A and B. We collected the patients' clinical data, evaluated their disease, and tested for factor inhibitors.We included 202 patients with hemophilia (median age at diagnosis: 0.13 years, range: birth-34.8 years). The patients included 198 male patients (98%), 148 patients with hemophilia A (73.3%), and 54 patients with hemophilia B (26.7%). The patients exhibited severe factor VIII activity (<1%; 121 patients; 5.2%), moderate activity (1-5%; 7 patients; 4.9%), and mild activity (14 patients; 9.9%). Among the patients with care-related data, most patients were treated for episodic bleeding (76.8%) or received prophylaxis (22.6%); 1 patient received both treatments. Among the patients with source-related data, the factor replacements were derived from plasma (48.4%), recombinant concentrates (22.9%), both sources (14.6%), or fresh frozen plasma (14.1%). Factor VIII inhibitors were observed in 43 (29.3%) of the 147 patients, and only 1 of the 54 patients developed factor IX inhibitors. Most patients who developed inhibitors had severe hemophilia (40/44; 90.9%), and inhibitors were also common among patients who received recombinant products (14/43; 32.6%).The Saudi prevalence of factor inhibitors was similar to those among other ethnic populations.
Collapse
Affiliation(s)
- Tarek Owaidah
- Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Center
- Center of Excellence in Thrombosis and Hemostasis, King Saud University
| | | | | | - Abdulrahman Almusa
- Department of Pediatric Hematology, King Faisal Specialist Hospital and Research Center
| | - Fawaz Alkasim
- Department of Pediatric Hematology, Ministry of Health, Riyadh
| | - Ahmed Tarawah
- Department of Pediatric Hematology, Ministry of Health, Medina
| | - Randa Al Nouno
- Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Center
| | | | - Fahad Alothman
- Department of Pediatric Hematology, Security Force Hospital
| | - Ali Alomari
- Department of Pediatric Hematology, National Guard Hospital
| | - Saud Abu-Herbish
- Department of Oncology, Security Forces Hospital, Riyadh, Saudi Arabia
| | | | - Khawar Siddiqui
- Department of Pediatric Hematology, King Faisal Specialist Hospital and Research Center
| | - Mansor Ahmed
- Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Center
| | | | - Mahasen Saleh
- Department of Pediatric Hematology, King Faisal Specialist Hospital and Research Center
| |
Collapse
|
7
|
Nazir HF, Al Lawati T, Beshlawi I, AlSharidah S, Elshinawy M, Alkasim F, Khanani MF, Tarawa A, Al Subhi T, Alrawas A, Al Riyami W, Al Kindi S, Al Saadi K, Al-Lamki S, Wali Y. Mode of delivery and risk of intracranial haemorrhage in newborns with severe haemophilia A: a multicentre study in Gulf region. Haemophilia 2015; 22:e134-8. [PMID: 26561042 DOI: 10.1111/hae.12842] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2015] [Accepted: 09/19/2015] [Indexed: 12/01/2022]
Abstract
INTRODUCTION The optimum mode of delivery in a known carrier of a haemophilia A is still an issue of debate. AIM This study was conducted to report a multicentre experience in Gulf Cooperation Council (GCC) on the incidence of intracranial haemorrhage (ICH) in newborns with severe haemophilia A delivered by different modalities. METHODS We have conducted a retrospective/prospective multicentre cohort study including a total of seven hospitals distributed in four GCC countries between 1998 and Jan 2015. A total of 163 patient with severe haemophilia A (factor VIII <1%) were enrolled in this study, age ranged between 2 weeks to 18 years. RESULTS Most of the patients were born by spontaneous vaginal delivery (SVD) (131, 80.4%), whereas 26 patients (16%) were born by CS and only six patients were born by instrumental delivery (3.7%), five of them by vacuum and one was delivered using forceps. Five out of 163 patients developed ICH during the first 2 weeks of life (3.1%). Two of them were born by SVD (2/131; 1.5%) and two were born by instrumental delivery (2/6; 33.3%). Only one patient among those who were born by caesarean section developed ICH (1/26; 3.8%). Assisted vaginal delivery was associated with a significant risk of ICH, in comparison to SVD and CS (P = 0.0093). CONCLUSION Normal vaginal delivery is still considered a safe journey through the birth canal for haemophilic newborns particularly in this area of the world. Larger prospective studies might be needed to define an evidence-based optimal mode of delivery for the haemophilia carrier expecting an affected child.
Collapse
Affiliation(s)
- H F Nazir
- Child Health Department, Sultan Qaboos University Hospital, Muscat, Oman.,Division of Hematology, Department of Pediatrics, Faculty of Medicine, Alexandria University, Alexandria, Egypt
| | - T Al Lawati
- Child Health Department, Sultan Qaboos University Hospital, Muscat, Oman
| | - I Beshlawi
- Child Health Department, Sultan Qaboos University Hospital, Muscat, Oman
| | - S AlSharidah
- Department of Pediatrics, Mubarak Alkabeer Hospital, Kuwait, Kuwait
| | - M Elshinawy
- Child Health Department, Sultan Qaboos University Hospital, Muscat, Oman.,Division of Hematology, Department of Pediatrics, Faculty of Medicine, Alexandria University, Alexandria, Egypt
| | - F Alkasim
- Pediatric Hematology Department, Children Hospital, King Saud Medical City, Riyadh, Saudi Arabia
| | - M F Khanani
- Department of Pediatrics, Tawam Hospital, Alain, UAE
| | - A Tarawa
- Hereditary Blood Disorders Center, King Abdullah Medical City, Madinah, Saudi Arabia
| | - T Al Subhi
- Child Health Department, Sultan Qaboos University Hospital, Muscat, Oman
| | - A Alrawas
- Child Health Department, Sultan Qaboos University Hospital, Muscat, Oman
| | - W Al Riyami
- Child Health Department, Sultan Qaboos University Hospital, Muscat, Oman
| | - S Al Kindi
- Child Health Department, Sultan Qaboos University Hospital, Muscat, Oman
| | - K Al Saadi
- Radiology Department, Diwan Medical Complex, Muscat, Oman
| | - S Al-Lamki
- Department of Haematology & Transfusion Medicine, Royal Hospital, Muscat, Oman
| | - Y Wali
- Child Health Department, Sultan Qaboos University Hospital, Muscat, Oman.,Division of Hematology, Department of Pediatrics, Faculty of Medicine, Alexandria University, Alexandria, Egypt
| |
Collapse
|
8
|
Alalayet YF, Alkasim F, Shiba N, Aldhuayan I, Alhamaidi S, Alghamdi G, Aljobair F, Shoura J, Alkhlaif R. A unique case of segmental vasal atresia. Res Rep Urol 2014; 6:145-7. [PMID: 25419520 PMCID: PMC4234156 DOI: 10.2147/rru.s41633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
We report a case of a 2-year-old boy who presented with an empty left scrotum. Clinical examination revealed a left palpable undescended testis. During orchidopexy, segmental atresia of the vas deferens was found, and microsurgical repair was carried out. Segmental vasal atresia is an extremely rare condition and is infrequently diagnosed, especially in the pediatric age group. This is the first reported case of segmental vasal atresia without an association with cystic fibrosis.
Collapse
Affiliation(s)
| | - F Alkasim
- Department of Pediatrics, King Saud Medical City, Riyadh, Saudi Arabia
| | - N Shiba
- Department of Pediatric Surgery, King Saud Medical City, Riyadh, Saudi Arabia
| | - I Aldhuayan
- Department of Pediatrics, King Saud Medical City, Riyadh, Saudi Arabia
| | - S Alhamaidi
- Department of Pediatric Surgery, King Saud Medical City, Riyadh, Saudi Arabia
| | - G Alghamdi
- Department of Pediatrics, King Saud Medical City, Riyadh, Saudi Arabia
| | - F Aljobair
- Department of Pediatrics, King Saud Medical City, Riyadh, Saudi Arabia
| | - J Shoura
- Department of Pediatric Surgery, King Saud Medical City, Riyadh, Saudi Arabia
| | - R Alkhlaif
- Department of Pediatrics, King Saud Medical City, Riyadh, Saudi Arabia
| |
Collapse
|
9
|
Jawad A, Najjar B, Shoura M, Alalayet Y, Alhamidi S, Alkasim F, Ghareeb E. Totally implanted vascular access devices: A retrospective study of indications and complications in a single pediatric institute. J Appl Hematol 2014. [DOI: 10.4103/1658-5127.131820] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|